



## Sebacoyl Isothiocyanate in the Synthesis of Bis (1,3,4-thiadiazole, 1,3,4-thiadiazolo[3,2-a]pyridine, 4-thiazolidinone, Chromenes, and Naphtho[1,2-b][1,4]oxazine) Derivatives

HAMDY KHAMEES THABET

Department of Chemistry, Faculty of Arts and Science, Northern Border University,  
Rafha-91911, PO 840, Saudi Arabia.

\*Corresponding author E mail: hamdykhamees@gmail.com

<http://dx.doi.org/10.13005/ojc/360215>

(Received: December 12, 2019; Accepted: April 28, 2020)

### ABSTRACT

Reaction of sebacoyl isothiocyanate with cyanoacetic acid hydrazide afforded  $N^1, N^0$ -bis (1,3,4-thiadiazole) derivative which used as key precursor for the preparation of bis (1,3,4-thiadiazolo[3,2-a]pyridine, 4-thiazolidinone, chromene, and naphtho[1,2-b][1,4]oxazine) derivatives. The chemical structures of novel compounds were proven by spectroscopic analyses.

**Keywords:** Sebacoyl isothiocyanate, 1,3,4-thiadiazoles, 1,3,4-thiadiazolo[3,2-a]pyridines, 4-thiazolidinone, Chromenes, Naphtho[1,2-b][1,4]oxazine.

### INTRODUCTION

Acyl isothiocyanates are predominant bioactive compounds having many biological activities and are versatile precursors to the preparation of sulfur-containing heterocycles<sup>1-7</sup>.

Among the wide range of heterocycles studied to develop pharmaceutically significant molecules, 1,3,4-thiadiazole has played a significant role in medicinal chemistry. Moreover, 1,3,4-thiadiazole nucleus has fascinated significance in medicinal chemistry, displaying pharmacological properties such as, antimicrobial<sup>8-10</sup>, anti-inflammatory<sup>11</sup>, antitumor<sup>12,13</sup>, anticonvulsant<sup>14,15</sup>, antioxidant<sup>16</sup>, antifungal<sup>17</sup>, antitubercular<sup>18</sup>, and antidepressant activities<sup>19</sup>.

In view of these results and in extension of our work on bioactive heterocycles<sup>20-28</sup>, we report herein the efficient preparation of bis (1,3,4-thiadiazolo[3,2-a]pyridine, 4-thiazolidinone, chromenes, and naphtho[1,2-b][1,4]oxazine) derivatives containing 1,3,4-thiadiazole starting from sebacoyl isothiocyanate as a key precursor.

### MATERIALS AND METHODS

The melting point, (<sup>1</sup>H/<sup>13</sup>C)-NMR, and elemental analysis data was obtained by the techniques described in our earlier reports<sup>20</sup>.

**$N^1, N^0$ -bis(5-(cyanomethylene)-4,5-dihydro-1,3,4-thiadiazol-2-yl)decanediamide (4)**

NH<sub>4</sub>SCN (1.52 g, 0.02 mol) and sebacoyl



chloride (2.39 g, 0.01 mol) in dioxane (30 mL) was mixed, then the mixture was stirred for 30 min and the precipitate was filtered off. To the remainder filtrate 2-cyanoacetohydrazide (1.98 g, 0.02 mol) in dioxane (15 mL) was added then refluxed for 5 hours. The reaction product was filtered, and left to dry, then crystallized to afford 4 (Table 1).

***N'*,*N'*<sup>0</sup>-Bis(5-(1-cyano-2-methylprop-1-en-1-yl)-1,3,4-thiadiazol-2-yl)decanediamide (5)**

NH<sub>4</sub>SCN (1.52 g, 0.02 mol) and sebacoyl chloride (2.39 g, 0.01 mol) in acetone (50 mL) was underwent stirring for thirty minutes at room temperature, and 2-cyanoacetohydrazide (1.98 g, 0.02 mol) was added. The solution underwent refluxing for 6 hours., cooled at the room temp. The reaction product was filtered, and left to dry, then crystallized to afford 5 (Table 1).

**Synthesis of *N'*,*N'*<sup>0</sup>-Bis(1,3,4-thiadiazol-2-yl)decanediamide (7a-c)**

General method: A mixture of 4 (0.01 mol), aromatic aldehydes 6a-c (0.02 mol), and pip. (3 drops) in EtOH (25 mL) underwent refluxing for 6 hours. The reaction product was filtered, and left to dry, then crystallized to afford 7a-c, (Table 1).

**Synthesis of *N'*,*N'*<sup>0</sup>-Bis(1,3,4-thiadiazolo(3,2-a)pyridine-2-yl)-decanediamide (9a-c).**

Method A: To compound 4 (0.01 mol) and requisite cinnamitrile (0.02 mol) in EtOH (30 mL), two piperidine drops was mixed. The reaction mixture was refluxed for three hours. The solution was cooled, the solid mass was filtered, then purified to afford 9a-c.

**Method B**

To a mixture of the requisite arylidene derivatives 7a-c (0.01 mol) and CH<sub>2</sub>(CN)<sub>2</sub> (0.02 mol) a few drops of piperidine in EtOH (30 mL) was added and refluxed for 4 hours. The formed precipitate was filtered, and then purified to afford 9a-c (Table 1).

***N'*,*N'*<sup>0</sup>-Bis(5-(cyano(2-oxoindolin-3-ylidene)methylene)-1,3,4-thiadiazol-2-yl)-decanediamide (10)**

To a compound 4 (0.446 g, 1 mmol) and isatin (0.294 g, 2 mmol) in EtOH (30 mL), three piperidine drops was added. The solution underwent refluxing for 2 hours. The solid mass on hot, was collected, dried, finally recrystallized to afford 10 (Table 1).

***N'*,*N'*<sup>0</sup>-Bis(5-(4-amino-3-phenyl-2-thioxo-2,3-dihydrothiazol-5-yl)-1,3,4-thiadiazol-2-yl)decanediamide (11)**

A mixture of 4 (0.446 g, 1 mmol), phenyl isothiocyanate (0.27 g, 2 mmol) and elemental sulfur (0.064 g, 2 mmol) in dioxane (30 mL) having Et<sub>3</sub>N (1 mL) was allowed to reflux for 3 hours. The reaction product was filtered, then recrystallized to afford 11 (Table 1).

***N'*,*N'*<sup>0</sup>-Bis(5-((4-oxo-4,5-dihydrothiazol-2-yl)methylene)-1,3,4-thiadiazol-2-yl)decanediamide (12)**

A solution of 4 (0.446 g, 1 mmol), and sulfanylacetic acid (0.184 g, 2 mmol) in AcOH (20 mL) underwent refluxing for 4 hours. The solid was collected and purified to afford 12 (Table 1).

**Synthesis of bis-chromene derivatives (14), (16) and Bis(naphtho[2,1-b][1,4]oxazine derivative (17)**

A mixture of 4 (0.446 g, 1 mmol), salicylaldehyde (0.244 g, 2 mmol); 2-hydroxy-1-naphthaldehyde (0.344 g, 2 mmol); 1-nitronaphthalen-2-ol (0.345 g, 2 mmol) and AcONH<sub>4</sub> (2 g) in EtOH (30 mL) underwent refluxing for two hours. The product mass was collected, washed with MeOH, dried, and finally purified to afford 14, 16 and 17 (Table 1).

**Synthesis of *N'*,*N'*<sup>0</sup>-Bis(5-(2-oxo-2H-chromen-3-yl)-1,3,4-thiadiazol-2-yl)-decane-diamide (15)**

**Method A**

A mixture of 4 (0.446 g, 1 mmol), salicylaldehyde (0.244 g, 2 mmol) and 0.5 g of fused AcONa in AcOH (30 mL) underwent refluxing for 2 hours. The formed product mass on cooling was collected, dried, and finally purified to afford 15, (Table 1).

**Method B**

To a refluxing solution of bis(iminochromene) derivative 14 (1.31 g, 2 mmol) in dioxane (30 mL) HCl (5 mL) was added. The refluxing was continuing for 2 h and left to cool. The obtainable solid was collected, washed with cold H<sub>2</sub>O, dried, and finally crystallized to afford 15.

**Table 1: Physical data of the compounds**

| Compd. No. | M.P. (°C) | Yield (%) Cryst. Solvent | Formula (Mol. Wt.)   | Elemental Analyses Calcd. /Found % |      |       |
|------------|-----------|--------------------------|--|------------------------------------|------|-------|
|            |           |                          |  | C                                  | H    | N     |
| 4          | 220-22    | (80)<br>(A)              | C <sub>18</sub> H <sub>22</sub> N <sub>8</sub> O <sub>2</sub> S <sub>2</sub><br>(446.55)                 | 48.42                              | 4.97 | 25.09 |
|            |           |                          |  | 48.27                              | 4.74 | 25.16 |
| 5          | 232-34    | (68)<br>(B)              | C <sub>24</sub> H <sub>30</sub> N <sub>8</sub> O <sub>2</sub> S <sub>2</sub><br>-526.68                  | 54.73                              | 5.74 | 21.28 |
|            |           |                          |  | 54.52                              | 5.49 | 21.10 |
| 7a         | 245-47    | (66)<br>(B)              | C <sub>32</sub> H <sub>30</sub> N <sub>8</sub> O <sub>2</sub> S <sub>2</sub><br>-622.77                  | 61.72                              | 4.86 | 17.99 |
|            |           |                          |  | 61.53                              | 4.70 | 17.76 |
| 7b         | 256-58    | (71)<br>(B)              | C <sub>34</sub> H <sub>34</sub> N <sub>8</sub> O <sub>2</sub> S <sub>2</sub><br>-682.82                  | 59.81                              | 5.02 | 16.41 |
|            |           |                          |  | 59.65                              | 4.89 | 16.28 |
| 7c         | 264-66    | (80)<br>(B)              | C <sub>32</sub> H <sub>28</sub> Cl <sub>2</sub> N <sub>8</sub> O <sub>2</sub> S <sub>2</sub><br>-691.65  | 55.57                              | 4.08 | 16.20 |
|            |           |                          |  | 55.42                              | 3.84 | 15.93 |
| 9a         | 279-81    | (55/53)<br>(B)           | C <sub>38</sub> H <sub>34</sub> N <sub>12</sub> O <sub>2</sub> S <sub>2</sub><br>-754.89                 | 60.46                              | 4.54 | 22.27 |
|            |           |                          |  | 60.31                              | 4.40 | 22.08 |
| 9b         | 284-86    | (80/74)<br>(B)           | C <sub>40</sub> H <sub>38</sub> N <sub>12</sub> O <sub>2</sub> S <sub>2</sub><br>-814.94                 | 58.95                              | 4.70 | 20.63 |
|            |           |                          |  | 58.70                              | 4.49 | 20.48 |
| 9c         | 290-92    | (88/85)<br>(B)           | C <sub>38</sub> H <sub>32</sub> Cl <sub>2</sub> N <sub>12</sub> O <sub>2</sub> S <sub>2</sub><br>-823.78 | 55.41                              | 3.92 | 20.40 |
|            |           |                          |  | 55.25                              | 3.71 | 20.25 |
| 10         | 275-77    | (81)<br>(B)              | C <sub>34</sub> H <sub>28</sub> N <sub>10</sub> O <sub>4</sub> S <sub>2</sub><br>-704.78                 | 57.94                              | 4.00 | 19.87 |
|            |           |                          |  | 57.76                              | 3.83 | 19.64 |
| 11         | 240-42    | (77)<br>(B)              | C <sub>32</sub> H <sub>32</sub> N <sub>10</sub> O <sub>2</sub> S <sub>6</sub><br>-781.04                 | 49.21                              | 4.13 | 17.93 |
|            |           |                          |  | 49.10                              | 3.96 | 17.71 |
| 12         | 263-65    | (74)<br>(B)              | C <sub>22</sub> H <sub>26</sub> N <sub>8</sub> O <sub>4</sub> S <sub>4</sub><br>-594.74                  | 44.43                              | 4.41 | 18.84 |
|            |           |                          |  | 44.27                              | 4.22 | 18.70 |
| 14         | 251-53    | (83)<br>(B)              | C <sub>32</sub> H <sub>30</sub> N <sub>8</sub> O <sub>4</sub> S <sub>2</sub><br>-654.76                  | 58.70                              | 4.62 | 17.11 |
|            |           |                          |  | 58.52                              | 4.45 | 16.89 |
| 15         | 285-87    | (75/60)<br>(B)           | C <sub>32</sub> H <sub>28</sub> N <sub>6</sub> O <sub>6</sub> S <sub>2</sub><br>-656.73                  | 58.52                              | 4.30 | 12.80 |
|            |           |                          |  | 58.36                              | 4.17 | 12.63 |
| 16         | 268-70    | (77)<br>(B)              | C <sub>40</sub> H <sub>34</sub> N <sub>8</sub> O <sub>4</sub> S <sub>2</sub><br>-754.88                  | 63.64                              | 4.54 | 14.84 |
|            |           |                          |  | 63.51                              | 4.39 | 14.67 |
| 17         | 289-91    | (80)<br>(B)              | C <sub>38</sub> H <sub>32</sub> N <sub>10</sub> O <sub>4</sub> S <sub>2</sub><br>-756.86                 | 60.30                              | 4.26 | 18.51 |
|            |           |                          |  | 60.18                              | 4.11 | 18.32 |

A = EtOH, B = dioxane

**Table 2: The characteristic spectroscopic data of 4, 5, 7a-c, 9a-c, 10-12, and 14-17**

| Comp. | IR                                       | <sup>1</sup> H-NMR   | <sup>13</sup> C-NMR  |
|-------|--|--|--|
| 4     | 3205, 2927, 2851, 2263, 1685, 1609       | 1.26 (brs, 8H.), 1.57 (m, 4H.), 2.36 (t, 4H.), 3.74 (s, 2H), 10.13 (s, 2H, 2NH)  | 18.73 (1C.), 25.06 (1C.), 28.93 (1C.), 29.04 (1C.), 34.10 (1C.), 116.94 (C=N), 154.07, 167.32 (C=N), 172.20 (C=O)  |
| 5     | 3209, 2926, 2851, 2252, 1691, 1609       | 1.26 (brs, 8H.), 1.56 (m, 4H.), 2.37 (t, 4H.), 2.23 (s, 3H), 2.39 (s, 3H), 10.16 (s, 2H, 2NH)  | 23.56 (1C), 24.03 (1C), 25.40 (1C.), 28.88 (1C.), 29.28 (1C.), 39.56 (1C.), 116.11 (C=N), 158.49, 164.36 (C=N), 171.41 (C=O)   |
| 7a    | 3190, 3017, 2939, 2853, 2215, 1687, 1587 | 1.28 (brs, 8H.), 1.56 (m, 4H.), 2.36 (t, 4H.), 7.04-7.35 (m, 10H, Ar-H), 8.45 (s, 2H, benzylidene-H), 10.12 (s, 2H, 2NH)             | 24.93 (1C.), 28.83 (1C.), 29.28 (1C.), 34.56 (1C.), 98.58 (C2), 116.11 (C=N), 146.15 (benzylidene'C), 127.55, 128.05, 131.11, 136.42 (Ar'C), 158.49, 164.36 (C=N), 171.41 (C=O)                                  |
| 7b    | 3209, 3050, 2925, 2851, 2205, 1682, 1610 | 1.29 (brs, 8H.), 1.54 (m, 4H.), 2.38 (t, 4H.), 3.83 (s, 3H), 7.13-7.26 (m, 8H, Ar-H), 7.97 (s, 2H, benzylidene-H), 9.85 (s, 2H, 2NH) | 24.68 (1C), 28.89 (1C.), 29.32 (1C.), 34.35 (1C.), 56.06 (1C), 116.54 (C=N), 99.64 (C2), 125.67, 129.77, 135.52, 142.16 (Ar'C), 147.60 (benzylidene'C), 158.70, 162.71 (C=N), 172.30 (C=O)                       |
| 7c    | 3307, 3093, 2939, 2860, 2206, 1680, 1601 | 1.28 (brs, 8H), 1.60 (m, 4H), 2.38 (t, 4H), 7.38-7.46 (m, 8H), 8.44 (s, 2H, benzylidene-H), s 9.95 (s, 2H, 2NH)                      | 22.09 (1C.), 28.65 (1C.), 29.15 (1C.), 34.34 (1C.), 115.41 (C=N), 94.06 (C2), 126.79, 127.43, 130.42, 133.48, 137.25 (Ar'C), 147.78 (benzylidene'C), 155.48, 163.56 (C=N), 173.21 (C=O)                          |
| 9a    | 3327, 3201, 2931, 2865, 2210, 1682,      | 1.26 (brs, 8H), 1.57 (m, 4H), 2.37 (t, 4H), 5.76 (s, 2H, pyridine H-4),  | 24.94 (1C.), 27.82 (1C.), 29.00 (1C.), 34.33 (1C.), 45.31 (C-7), 63.21 (C-6), 101.15 (C-8), 115.81, 116.30 (C=N), 155.98 (C-5), 126.55, 128.62, 131.11, 136.42 (Ar'C), 151.49 (C-8a), 161.90 (C-2), 171.41 (C=O) |

| Comp. | IR   | <sup>1</sup> H-NMR  | <sup>13</sup> C-NMR  |
|-------|--|---|--|
| 9b    | 3364, 3214, 2926, 2853, 2216, 1677, 1612       | 1.26 (brs, 8H), 1.56 (m, 4H), 2.38 (t, 4H), 3.78 (s, 3H), 5.83 (s, 2H, pyridine H-4), 6.31 (br.s, 4H, 2NH <sub>2</sub> ), 7.19-7.32 (m, 8H, Ar-H), 10.05 (s, 2H, 2NH) | 25.02 (1C.), 27.65 (1C.), 28.45 (1C.), 34.16 (1C.), 46.71 (C-7), 64.58 (C-6), 100.83 (C-8), 115.20, 117.11 (C=N), 156.44 (C-5), 126.49, 128.75, 131.28, 137.23 (Ar'C), 152.51 (C-8a), 160.82 (C-2), 172.34 (C=O) |
| 9c    | 3331, 3256, 2918, 2847, 2224, 1680, 1605       | 1.27 (brs, 8H), 1.56 (m, 4H), 2.37 (t, 4H), 5.79 (s, 2H, pyridine H-4), 6.20 (brs, 4H, 2NH <sub>2</sub> ), 7.25-7.41 (m, 8H, Ar-H), 10.16 (s, 2H, 2NH)                | 25.15 (1C.), 27.41 (1C.), 28.90 (1C.), 33.89 (1C.), 47.25 (C-7), 65.18 (C-6), 99.74 (C-8), 115.55, 116.28 (C=N), 155.21 (C-5), 127.35, 128.86, 130.26, 137.06 (Ar'C), 153.59 (C-8a), 161.15 (C-2), 171.37 (C=O)  |
| 10    | 3208, 3173, 3053, 2925, 2852, 1700, 1676, 1609 | 1.28 (brs, 8H), 1.61 (m, 4H), 2.37 (t, 4H), 7.10-8.11 (m, 8H, Ar-H), 10.35, 11.51 (brs, 4H, 4NH)  | 23.86 (1C.), 26.45 (1C.), 27.35 (1C.), 34.22 (1C.), 114.75 (C-C=N), 117.21 (C=N), 112.95, 124.36, 125.37, 126.24, 128.61, 142.74 (Ar'C), 154.65 (indoline-C3), 155.32, 162.44 (C-2, C-5), 169.81, 173.37 (C=O)   |
| 11    | 3350, 3240, 3161, 3061, 2925, 2853, 1690, 1619 | 1.26 (brs, 8H), 1.55 (m, 4H), 2.39 (t, 4H), 6.58 (s, 4H, 2NH <sub>2</sub> ), 7.34-7.63 (m, 10H, ArH), 10.10 (s, 2H, 2NH)  | 24.92 (1C.), 25.38 (1C.), 28.67 (1C.), 34.19 (1C.), 83.35 (thiazolidine'C), 129.33, 129.40, 130.59, 1605, 130.63, 135.60 (Ar'C), 146.05 (thiazolidine'C), 154.86, 154.96 (C=N), 171.84 (C=O), 185.70 (C=S)       |
| 12    | 3209, 3051, 2923, 2851, 1732, 1681,            | 1.27 (brs, 8H), 1.59 (m, 4H), 2.38 (t, 4H), 3.84 (s, 2H), 4.13 (s, 2H), 10.15 (s, 2H, 2NH)  | 24.14 (1C.), 25.40 (1C.), 28.89 (1C.), 34.33 (1C.), 39.96 (1C.), 45.63 (1C), 161.64, 163.02, 167.32 (3C=N),  |
| Comp. | IR   | <sup>1</sup> H-NMR  | <sup>13</sup> C-NMR  |
|       | 1609   |   | 171.98, 178.21 (2C=O)  |
| 14    | 3283, 3135, 3021, 2928, 2854, 1678, 1637       | 1.29 (brs, 8H), 1.57 (m, 4H), 2.37 (t, 4H), 7.40-8.13 (m, 8H, Ar-H), 8.50 (s, 2H, chromene-H4), 9.16 (s, 2H, 2NH), 10.35 (s, 2H, 2NH)                                 | 25.31 (1C.), 26.21 (1C.), 28.63 (1C.), 34.51 (1C.), 116.41, 118.71, 120.08, 127.64, 129.82, 130.93, 132.87, 153.45 (Ar'C), 155.67, 158.16 (C=N), 168.68 (C=NH), 171.94 (C=O)                                     |
| 15    | 3225, 3133, 3042, 2944, 2861, 1740, 1694, 1616 | 1.28 (brs, 8H), 1.55 (m, 4H), 2.38 (t, 4H), 7.28-8.23 (brs, 8H, Ar-H), 8.63 (s, 2H, chromene-H4), 10.40 (s, 2H, 2NH)  | 25.36 (1C.), 26.55 (1C.), 29.23 (1C.), 34.68 (1C.), 115.89, 119.28, 121.43, 127.82, 129.56, 130.14, 131.74, 153.63 (Ar'C), 156.31, 159.24 (C=N), 163.26, 169.57 (C=O)  |
| 16    | 3277, 3158, 3044, 2921, 2835, 1682, 1614       | 1.28 (brs, 8H), 1.55 (m, 4H), 2.37 (t, 4H), 7.24-8.16 (m, 12H, Ar-H), 8.84 (s, 2H, benzochromene-H4), 9.65 (s, 2H, 2NH), 10.49 (s, 2H, 2NH)                           | 25.51 (1C.), 27.33 (1C.), 28.69 (1C.), 34.62 (1C.), 119.28, 121.08, 122.43, 123.08, 126.13, 129.60, 132.87, 133.48, 145.23, 153.79 (Ar'C), 154.80, 158.25 (C=N), 167.33 (C=NH), 174.83 (C=O)                     |
| 17    | 3324, 3170, 3022, 2942, 2853, 1673, 1608       | 1.29 (brs, 8H), 1.56 (m, 4H), 2.39 (t, 4H), 7.12-8.34 (m, 12H, Ar-H), 8.97 (s, 2H, 2NH.), 10.26 (s, 2H, 2NH)  | 26.12 (1C.), 27.68 (1C.), 29.08 (1C.), 34.15 (1C.), 118.35, 123.62, 125.53, 126.42, 127.74, 128.36, 130.25, 132.10, 144.61, 154.52 (Ar'C), 155.75, 157.32 (C=N), 162.49 (C=NH), 172.78 (C=O)                     |


## RESULTS AND DISCUSSION

The starting material, *N*<sup>1</sup>,*N*<sup>10</sup>-bis(5-cyanomethyl)-1,3,4-thiadiazol-2-yl)decane-diamide **4** was obtained via one-pot sequential reaction of sebacoyl chloride **1** with ammonium thiocyanate and cyanoacetic acid hydrazide **2** upon refluxing in dioxane. It is assumed that **1** reacts initially with sebacoyl isothiocyanate to yield the bis-(thiosemicarbazide) derivative **3** as intermediate which experienced cyclization to yield the bis(1,3,4-thiadiazole) **4** (Scheme 1).

Repeating the reaction in acetone as a solvent, the bis(1,3,4-thiadiazole) derivative **5**

was obtained. IR spectrum (cm<sup>-1</sup>) of **4** revealed 3205 (NH), 2927, 2851 (aliphatic-H), 2263 (C≡N), 1685 (C=O). Its <sup>1</sup>H-NMR spectrum (DMSO-*d*<sub>6</sub>, δ ppm) revealed a broad singlet signal at 1.26 corresponding to four methylene groups, a multiplet at 1.57 corresponding to two methylene groups, triplet at 2.36 corresponding to two CH<sub>2</sub>CO, 3.74 corresponding to CH<sub>2</sub>CN, and singlet at 10.13 attributed to imino group. <sup>13</sup>C-NMR spectrum of **4** exhibited signals at 18.73, 25.06, 28.93, 29.04, 34.10 and 46.22 for the methylene carbons, a signal at 116.94 due to the cyano carbons, two signals at 154.07, 167.32 related to the C=N carbons, a signal at 172.20 ascribed to carbonyl carbons. <sup>1</sup>H-NMR spectrum of **5** displayed signals at 2.23 and


2.41 corresponding to  $2\text{CH}_3$  groups with a singlet at 10.16 attributed to NH group in addition to protons of sebacyl moiety.



**Scheme 1.** Preparation of Compounds 4 and 5


Knoevenagel condensation of bis(1,3,4-thiadiazole) derivative **4** with aromatic aldehydes **6a-c** afforded bis(arylidene)s **7a-c** (Scheme 2). IR spectrum ( $\text{cm}^{-1}$ ) of **7a** revealed 1687, 2215, 2853, 2939, 3017, 3190 attributed to C=O, C≡N, aliphatic, aromatic and imino functional groups. Its  $^1\text{H-NMR}$  spectrum exhibited signals at 8.45 & 10.12 due to benzyldiene-H and imino protons together with aromatic protons at 7.04-7.35 in addition to the sebacyl hydrogen's.

Refluxing of compound **4** with arylidene-malononitriles **8a-c** in ethanol/piperidine gave bis(1,3,4-thiadiazolo[3,2-a]pyridines) **9a-c** in good yields. Compounds **9a-c** were also achieved via refluxing of the arylidenes **7a-c** with malononitrile under the same conditions. Compound **4** react with two equivalents of isatin in refluxing ethanol/piperidine and afforded bis(indoline) derivative **10** (Scheme 2).



**Scheme 2.** Preparation of compounds 7a-c, 9a-c and 10

Ternary condensation of compound **4**, elemental sulfur and phenyl isothiocyanate (in 1:2:2 molar ratio) in dioxane containing triethylamine afforded **11** (Scheme 3). The construction of the product took place in parallel to the reported Hantzsch reaction reported reaction<sup>29</sup>. The infrared spectrum ( $\text{cm}^{-1}$ ) of **11** showed significant absorption bands for  $\text{NH}_2$  and NH groups at 3350, 3240, 3161,  $\nu\text{C}=\text{O}$  at 1690, and  $\nu\text{C}=\text{N}$  at 1619.  $^1\text{H-NMR}$  spectrum displayed signals characteristic for imino proton at 10.10, aromatic protons as multiplet at 7.34-7.63, and singlet at 6.58  $\text{NH}_2$  group disappeared with  $\text{D}_2\text{O}$ , together with other signals which are regular with the suggested structure. Moreover, cyclocondensation of **4** with thioglycolic acid in acetic acid at reflux temperature gave bis(4-thiazolidinone) derivative **12** in good yield (Scheme 3). IR spectrum ( $\text{cm}^{-1}$ ) displayed the lack of a carbonitrile band and presence of absorption bands at 3209, 3051, 2923, 2851, 1732, 1681 corresponding to NH, aromatic, aliphatic, and carbonyl functional groups.  $^1\text{H-NMR}$  spectrum indicated the presence of two singlets of equal integrals at 3.84 and 4.13 which was corresponding for two different methylene groups with singlet at 10.15 assigned for 2 NH beside presence of sebacyl hydrogen's. The construction of compound **12** may be supposed to form via primary addition of the mercapto group in the reagent to the cyano group in compound **4** which undergo intramolecular cyclization by loss of two water molecules.




**Scheme 3.** Preparation of compounds 11,12

Chromene derivatives were reported to have a widespread biological properties<sup>30</sup>. Thus, cyclocondensation of compound **4** with salicylaldehyde and/or 2-hydroxynaphthaldehyde in

ethanol/ammonium acetate gave bis(chromene) **14** and bis(benzochromene) **16** (Scheme 4). Moreover, cyclocondensation of **4** with salicylaldehyde in acetic acid catalyzed with fused sodium acetate gave bis(coumarin) derivative **15**. Compound **15** was also prepared via hydrolysis of **14** with HCl. IR spectrum ( $\text{cm}^{-1}$ ) of **14** displayed absorption bands at 3283, 3135, 1678 assignable to NH & C=O functions. Its  $^1\text{H-NMR}$  spectrum exhibited two signals at 9.16 and 10.35 due to 2 NH protons, singlet at 8.50 due to chromene-H beside aromatic protons at 7.40-8.13 beside the protons of sebacoyl moiety.  $^1\text{H-NMR}$  spectrum of **15** exhibited  $\text{D}_2\text{O}$ -exchangeable signal at 10.20 two CONH protons, in addition to sebacoyl protons. Finally, cyclocondensation of compound **4** with 1-nitroso-2-naphthol in refluxing ethanol catalyzed with ammonium acetate gave bis(naphtho[2,1-b][1,4]oxazine) derivative **17** (Scheme 4). IR ( $\text{cm}^{-1}$ ) of **17** showed bands at 3324, 3170 (NH). Its  $^1\text{H-NMR}$  spectrum exhibited a multiplet at 7.12–8.34, ascribed to aromatic protons, and two  $\text{D}_2\text{O}$ -exchangeable singlet at 8.97, 10.26 for NH protons.

## CONCLUSION

A facile and appropriate synthesis of some unique bis (thiadiazoles, 4-thiazolidinone, chromenes, 1,3,4-thiadiazolo[3,2-a]pyridines and naphtho[2,1-b]oxazines) containing sebacoyl spacer has been described. The chemical structure interpretations of the titled compounds were attained using elemental analyses,  $^1\text{H}$  &  $^{13}\text{C-NMR}$ .



Scheme 4. Preparation of compounds 14-17

## ACKNOWLEDGEMENT

The author would like to express his deep gratitude to the Northern Border University, Kingdom of Saudi Arabia for providing financial support of this research (project 2017-1-F- 7038).

## Conflicts of interest

There are no conflicts of interest.

## REFERENCES

- Saini, K.M.; Saunthwal, R.K.; Kumar, S. *Org. Biomol. Chem.*, **2019**, *17*, 2657-2662.
- Manaka, A.; Ishii, T.; Takahashi, K.; Sato, M. *Tetrahedron Lett.*, **2005**, *46*, 419-422.
- Piscitelli, F.; Ballatore C., Smith, A.B. *Bioorg. Med. Chem. Lett.*, **2010**, *20*, 644-648.
- Diana, P.; Barraja P.; Lauria A. *Bioorg. Med. Chem.*, **2003**, *11*, 2371-2380.
- Sadchikova, E.V.; Bakulev, V.A.; Subbotina, J.O. *Tetrahedron.*, **2013**, *69*, 6987-6992.
- Varshney, K.; Gupta, A.K.; Rawat, A. *Chemical Biology & Drug Design.*, **2019**, *94*(1), 1378-1389.
- Hemdan, M.M.; Fahmy, AF, El-Sayed, AA. *J. Chem. Res.*, **2010**, *34*(4), 219-221.
- Rezki, N.; Al-Yahyawi, A.M.; Bardaweel, S.K.; Al-Blewi, F.F.; Aouad, M.R.; *Molecules.*, **2015**, *20*(9), 16048–16067.
- El-Sayed, W.A.; Metwally, M.A.; Nada, D.S. Abdel-Rahman A.A.H. *J. Heterocycl. Chem.*, **2013**, *50*, 194–201.
- Bayrak, H.; Demirbas, A.; Demirbas, N.; Karaoglu, S.A. *Eur. J. Med. Chem.*, **2010**, *45*(11), 4726–4732.
- Kadi, A.A.; Al-Abdullah, E.S.; Shehata, I.A.; Habib, E.E.; Ibrahim, T.M.; El-Emam, A.A.; *Eur. J. Med. Chem.*, **2010**, *45*(11), 5006–5011.
- El-Naggar, M.; Sallam, H.; Shaban, A. S. S.; Abdel-Wahab, S. S.; Amr, A. E.; Azab, M. E.; Nossier, E. S.; Al-Omar, M. A. *Molecules.*, **2019**, *24*, 1066-1081.
- Altıntop, M. D.; Ciftci, H. I.; Radwan, M. O.; Sever, B.; Kaplancıklı, Z. A.; Ali, T. F. S.; Koga, R.; Fujita, M.; Otsuka, M.; Özdemir, A.; *Molecules.*, **2018**, *23*, 59-75.

14. Karakus, S.; Kocyigit-Kaymakcioglu, B.; Toklu, H.Z.; Aricioglu F, Rollas S. *Arch. Pharm.*, **2009**, *342*, 48-53.
15. Diaz, J.R.; Camí, G.E.; Liu-González, M.; Vega, D.R.; Vullo, D.; Juárez, A.; Pedregosa, J.C.; Supuran, C.T. *J. Enzyme Inhib. Med. Chem.*, **2016**, *31*(6), 1102-1110.
16. Jakovljevi K.; Joksovi MD.; Mati IZ.; Petrovi N.; Stanojkovi T.; Sladi D.; Vuj i M.; Janovi B.; Joksovi L.; Trifunovi S.; Markovi V.; *Medchemcomm.*, **2018**, *9*(10), 1679-1697.
17. El-Badry, Y, A.; Sallam M.S.; El-Hashash, M. A. *Chem. Pharm. Bull. (Tokyo)*., **2018**, *66*(4), 427-433.
18. Ramprasad, J.; Nayak, N.; Dalimba, U. *Eur. J. Med. Chem.*, **2015**, *106*, 75-84.
19. Jubie, S.; Ramesh, P.N.; Dhanabal, P.; Kalirajan, R.; Muruganatham, N.; Antony, A.S. *Eur. J. Med. Chem.*, **2012**, *54*, 931-935.
20. El-Feky, S.A., Thabet, H.Kh. and Ubied, M.T. *J. Fluor. Chem.*, **2014**, *161*, 87-94.
21. Ammar, Y.A.; Al-Sehemi, A.G.; Ali, M.M.; Mohamed, Y.A.; Thabet, H.Kh.; El-Gaby, M.S.A.; *Heterocycl. Lett.*, **2015**, *5*(2), 157-167.
22. Ubied, M.T.; Thabet, H.Kh.; El-Feky, S.A. *Heterocycl. Commun.*, **2016**, *22*(1), 43-47.
23. Farrag, A.A.; Ammar Y.A.; El-Sehemi, A.G.; Thabet, H.Kh.; Hassan N. A.; Samy, A. Kh. *J. Chem. Res.*, **2011**, *35*, 163-166.
24. El-Feky, S. A.; Abd El-Samii, Z. K.; Osman, N. A.; Lashine, J.; Kamel M. A.; Thabet, H. Kh. *Bioorg. Chem.*, **2015**, *58*, 104-116.
25. Elzahabi, H.S.A.; Salem, M.A. Thabet, H.Kh. *Der Pharma Chem.*, **2011**, *3*, 48-58.
26. Ammar, Y.A.; Thabet, H.Kh.; Ali, M.M.; Mohamed Y. A.; Ismail, M. A.; Salem, M. A. *Phosph. Sulfur Silicon.*, **2010**, *185*(4), 743-753.
27. Hessein, S.A.; El-Sharief, M.A.M. Sh.; Abbas, S.Y.; Thabet, H.Kh.; Ammar, Y. A. *Croat. Chem. Acta.*, **2016**, *89*(1), 91-100.
28. Thabet, H.Kh.; Ubied, M.T.; El-Feky, S.A. *J. Chem. Res.*, **2015**, *39*(10), 567-573.
29. Tormos, G.V.; Khodorkovsky, V.Yu.; Neilands, O.Ya., Belyakov, S.V. *Tetrahedron.*, **1992**, *48*, 6863-6874.
30. Ammar, Y.A.; El-Gaby, M.S.A.; Salem, M.A. *Arabian Journal of Chemistry.*, **2014**, *7*, 615-622.